Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
ARCHIVE Janssen to Differentiate Risperdal from Generics
July 30, 2007
-
ARCHIVE Major Medical Systems Used for 10.3 Years
July 30, 2007
-
ARCHIVE Alfresa to Reduce SGA Expanses Ratio to Below 6% by FY2009
July 30, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
July 30, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Benefits for OTC-Like Ethical Drugs to Be Reviewed in 4 to 5 Years
July 30, 2007
-
ARCHIVE 11 Generic Products (6 APIs) to Be Listed in November
July 30, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
July 30, 2007
-
ARCHIVE NPhA to Further Promote Use of Generics
July 30, 2007
-
ARCHIVE OPINION/Once in a Lifetime
July 30, 2007
-
ARCHIVE MD Studies to Be Permitted at a Total Dose of 500 μg: Dr Ohno
July 30, 2007
-
ARCHIVE TOPICS/Mebix Starts Home Blood Pressure Management Service
July 30, 2007
-
ARCHIVE RIKEN, Harvard Univ. Hospital Decipher Protein Structure of LTC4 Synthase
July 30, 2007
-
ARCHIVE Nutrition Management Improves QOL, Reduces Costs: Prof. Ohyanagi
July 30, 2007
-
ARCHIVE NanoCarrier Obtains Patent on Macromolecular Micelles
July 30, 2007
-
ARCHIVE Adiponectin Stimulates Appetite in the Brain: Prof. Kadowaki
July 30, 2007
-
ARCHIVE Exelon Patch Approved for Alzheimer's Disease: Novartis
July 23, 2007
-
ARCHIVE Price Agreement Rate Rose to 92.4% as of End of March
July 23, 2007
-
ARCHIVE R&D NEWS IN BRIEF
July 23, 2007
-
ARCHIVE Promote Multinational Clinical Trials to Eliminate Drug Lag: Study Group
July 23, 2007
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…